CA2827157A1 - Cathepsin c inhibitors - Google Patents
Cathepsin c inhibitors Download PDFInfo
- Publication number
- CA2827157A1 CA2827157A1 CA2827157A CA2827157A CA2827157A1 CA 2827157 A1 CA2827157 A1 CA 2827157A1 CA 2827157 A CA2827157 A CA 2827157A CA 2827157 A CA2827157 A CA 2827157A CA 2827157 A1 CA2827157 A1 CA 2827157A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441840P | 2011-02-11 | 2011-02-11 | |
| US61/441,840 | 2011-02-11 | ||
| PCT/US2012/024428 WO2012109415A1 (en) | 2011-02-11 | 2012-02-09 | Cathepsin c inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2827157A1 true CA2827157A1 (en) | 2012-08-16 |
Family
ID=46638952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2827157A Abandoned CA2827157A1 (en) | 2011-02-11 | 2012-02-09 | Cathepsin c inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8841463B2 (enExample) |
| EP (1) | EP2672821B9 (enExample) |
| JP (1) | JP5931929B2 (enExample) |
| KR (1) | KR20140048857A (enExample) |
| CN (1) | CN103491777B (enExample) |
| AR (1) | AR085163A1 (enExample) |
| AU (1) | AU2012214405B2 (enExample) |
| BR (1) | BR112013020510A2 (enExample) |
| CA (1) | CA2827157A1 (enExample) |
| CL (1) | CL2013002325A1 (enExample) |
| CO (1) | CO6741219A2 (enExample) |
| DO (1) | DOP2013000182A (enExample) |
| EA (1) | EA023168B1 (enExample) |
| ES (1) | ES2583091T3 (enExample) |
| IL (1) | IL227814A0 (enExample) |
| MA (1) | MA34961B1 (enExample) |
| MX (1) | MX2013009279A (enExample) |
| PE (1) | PE20140999A1 (enExample) |
| PH (1) | PH12013501665A1 (enExample) |
| SG (1) | SG192669A1 (enExample) |
| TW (1) | TW201302736A (enExample) |
| UY (1) | UY33905A (enExample) |
| WO (1) | WO2012109415A1 (enExample) |
| ZA (1) | ZA201306074B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| SG11201806700RA (en) * | 2016-02-12 | 2018-09-27 | Pharmaxis Ltd | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
| WO2023243601A1 (ja) | 2022-06-13 | 2023-12-21 | モジュラス株式会社 | アザシクロアルキルカルボニル環状アミン化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
| US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| CN1240355A (zh) * | 1996-05-01 | 2000-01-05 | 伊莱利利公司 | 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途 |
| US6214799B1 (en) | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
| AU2002232558A1 (en) * | 2000-12-12 | 2002-06-24 | Corvas International, Inc. | Compounds, compositions and methods for treatment of parasitic infections |
| CN101675052A (zh) | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
| EA201190235A1 (ru) * | 2009-05-07 | 2012-05-30 | Астразенека Аб | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 |
| UY32827A (es) * | 2009-08-12 | 2011-02-28 | Glaxo Group Ltd | Inhibidores de catepsina c |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
-
2012
- 2012-02-09 US US13/984,061 patent/US8841463B2/en not_active Expired - Fee Related
- 2012-02-09 EA EA201391155A patent/EA023168B1/ru not_active IP Right Cessation
- 2012-02-09 PE PE2013001836A patent/PE20140999A1/es not_active Application Discontinuation
- 2012-02-09 KR KR1020137023618A patent/KR20140048857A/ko not_active Ceased
- 2012-02-09 ES ES12744272.1T patent/ES2583091T3/es active Active
- 2012-02-09 JP JP2013553538A patent/JP5931929B2/ja not_active Expired - Fee Related
- 2012-02-09 WO PCT/US2012/024428 patent/WO2012109415A1/en not_active Ceased
- 2012-02-09 MX MX2013009279A patent/MX2013009279A/es not_active Application Discontinuation
- 2012-02-09 CN CN201280017698.7A patent/CN103491777B/zh not_active Expired - Fee Related
- 2012-02-09 CA CA2827157A patent/CA2827157A1/en not_active Abandoned
- 2012-02-09 BR BR112013020510A patent/BR112013020510A2/pt not_active IP Right Cessation
- 2012-02-09 SG SG2013060165A patent/SG192669A1/en unknown
- 2012-02-09 TW TW101104141A patent/TW201302736A/zh unknown
- 2012-02-09 PH PH1/2013/501665A patent/PH12013501665A1/en unknown
- 2012-02-09 EP EP12744272.1A patent/EP2672821B9/en active Active
- 2012-02-09 AU AU2012214405A patent/AU2012214405B2/en not_active Ceased
- 2012-02-09 MA MA36229A patent/MA34961B1/fr unknown
- 2012-02-09 UY UY0001033905A patent/UY33905A/es unknown
- 2012-02-10 AR ARP120100455A patent/AR085163A1/es unknown
-
2013
- 2013-08-05 IL IL227814A patent/IL227814A0/en unknown
- 2013-08-09 CO CO13190045A patent/CO6741219A2/es unknown
- 2013-08-09 CL CL2013002325A patent/CL2013002325A1/es unknown
- 2013-08-09 DO DO2013000182A patent/DOP2013000182A/es unknown
- 2013-08-13 ZA ZA2013/06074A patent/ZA201306074B/en unknown
-
2014
- 2014-08-21 US US14/464,734 patent/US9187461B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287880B2 (en) | 1R,2S,5S)-N-{(1S)-1-CYANO-2-[(3S)-2-OXOPYRROLIDIN-3-YL]ETHYL}-6,6-DIMETHYL-3-[3-METHYL-N - (TRIFLUOROACETYL)-L-VALYL]-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE and pharmaceutical compounds that make it up | |
| WO2014091443A1 (en) | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis | |
| JP6441830B2 (ja) | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤 | |
| US20160229839A1 (en) | Factor XIa Inhibitors | |
| ES3059451T3 (en) | Compound used as ret kinase inhibitor and application thereof | |
| US9187461B2 (en) | Cathepsin C inhibitors | |
| CN113195515B (zh) | 新的二肽类化合物及其用途 | |
| WO2012112733A1 (en) | Cathepsin c inhibitors | |
| WO2011025799A1 (en) | Cathepsin c inhibitors | |
| NZ614540B2 (en) | Cathepsin c inhibitors | |
| KR20120061870A (ko) | 카텝신 ｃ 억제제 | |
| EP4357335A1 (en) | Azabicyclo[3.1.0]hexane compound | |
| WO2017051761A1 (ja) | 新規なプロドラッグ | |
| WO2001010844A1 (fr) | DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170110 |
|
| FZDE | Discontinued |
Effective date: 20190211 |